Logo

MDxHealth AssureMDx for Bladder Cancer Liquid Biopsy Test

Jul 06, 2017

MDxHealth has launched its AssureMDx for Bladder Cancer liquid biopsy test in the US as a laboratory-developed test. AssureMDx is a non-invasive, urine-based test. It searches for methylation and mutation biomarkers in order to assess the risk of bladder cancer for patients diagnosed with hematuria. The test's 93 percent sensitivity and 85 percent specificity can help doctors identify patients at increased risk for bladder cancer, who may benefit from cystoscopy, the company said. Testing will be conducted at MDxHealth's CAP- and CLIA-accredited lab in Irvine, California.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.